These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11019980)

  • 1. Influence of fluvastatin on levels of von Willebrand factor in cardiac transplant recipients.
    Blann AD
    Thromb Haemost; 2000 Sep; 84(3):514. PubMed ID: 11019980
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients.
    Ambrosi P; Aillaud MF; Habib G; Kreitmann B; Métras D; Luccioni R; Bouvenot G; Juhan-Vague I
    Thromb Haemost; 2000 Jan; 83(1):46-8. PubMed ID: 10669153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential warfarin-fluvastatin interaction.
    Kline SS; Harrell CC
    Ann Pharmacother; 1997 Jun; 31(6):790. PubMed ID: 9184730
    [No Abstract]   [Full Text] [Related]  

  • 4. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient.
    Basic-Jukic N; Kes P; Bubic-Filipi L; Vranjican Z
    Nephrol Dial Transplant; 2010 Jun; 25(6):2036; author reply 2036-7. PubMed ID: 20332417
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
    Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
    Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.
    Miroševic Skvrce N; Božina N; Zibar L; Barišic I; Pejnovic L; Macolic Šarinic V
    Pharmacogenomics; 2013 Sep; 14(12):1419-31. PubMed ID: 24024895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential interaction between warfarin and fluvastatin.
    Trilli LE; Kelley CL; Aspinall SL; Kroner BA
    Ann Pharmacother; 1996 Dec; 30(12):1399-402. PubMed ID: 8968451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune hepatitis after treatment with fluvastatin.
    Castiella A; Fernandez J; Zapata E
    Liver Int; 2007 May; 27(4):592. PubMed ID: 17403199
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug of the month. Fluvastatin (Lescol)].
    Scheen AJ
    Rev Med Liege; 1997 Jun; 52(6):442-4. PubMed ID: 9289778
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of cyclosporine A on the release of tissue factor pathway inhibitor from endothelial cells in heart transplant patients and cell culture.
    Tiemann C; Prohaska W; Körfer R; Körner M; Brinkmann T; Kleesiek K
    Eur J Clin Chem Clin Biochem; 1997 Sep; 35(9):661-7. PubMed ID: 9352228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal lupus-like syndrome and ARDS induced by fluvastatin.
    Sridhar MK; Abdulla A
    Lancet; 1998 Jul; 352(9122):114. PubMed ID: 9672281
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
    Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients.
    Ghods AJ; Milanian I; Arghani H; Ghadiri G
    Transplant Proc; 1995 Oct; 27(5):2579-80. PubMed ID: 7482835
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
    Fellström B; Holdaas H; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Logan JO; Pedersen TR;
    Kidney Int; 2004 Oct; 66(4):1549-55. PubMed ID: 15458450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction.
    Westphal S; Abletshauser C; Luley C
    Coron Artery Dis; 2009 Jan; 20(1):81-5. PubMed ID: 19060628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More on: Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells.
    Musial J; Rys D; Brozek J; Swadzba J; Iwaniec T
    J Thromb Haemost; 2005 Mar; 3(3):614-5; author reply. PubMed ID: 15748273
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
    Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients.
    Bader T; Hughes LD; Fazili J; Frost B; Dunnam M; Gonterman A; Madhoun M; Aston CE
    J Viral Hepat; 2013 Sep; 20(9):622-7. PubMed ID: 23910646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.